Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind Study of Dacarbazine With or Without Genasense in Chemotherapy-naive Subjects With Advanced Melanoma and Low LDH (The AGENDA Trial)

NCT00518895 is registered in ClinicalTrials.gov with Genta Incorporated as lead sponsor.

NCT NCT00518895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00518895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind Study of Dacarbazine With or Without Genasense in Chemotherapy-naive Subjects With Advanced Melanoma and Low LDH (The AGENDA Trial)
Lead sponsor
Genta Incorporated
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2007
Completion date
May 31, 2011
Enrollment
300 (estimated)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma